Title: An Isoflavonoid Modulator of Oxidative Metabolism with Therapeutic Potential in Obesity and Diabetes (WE-868) Date and Time: Tuesday, November 4, 2025 at 7:30 p.m. - 8:30 p.m. ET Presenter: ...

Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participan ...

Terns Pharmaceuticals' trial data from its oral GLP-1 treatment for obesity missed a high threshold for efficacy, safety and tolerability. The biopharmaceutical company said Tuesday it will not ...

Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse eventsAsymptomatic, reversible grade ...

A closely watched pill from Novo Nordisk just scored an approval for slashing cardiovascular risks, while Mark Cuban gives ...

Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...

Weight loss drugs are in high demand, but most employers can’t shoulder the cost as health care rates skyrocket.

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular ...

BLOOM (TAMPA)- One of the culprits of hair loss may be more surprising than you think. Gayle Guyardo, host of Bloom, sat down with Board Certified Dermatologist, Dr. Summer Moon, and Medical Doctor, ...

Topline data were announced from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 diabetes.